Antibacterial and cytotoxicity assessment of poly (N-vinyl imidazole)/nitrogen-doped graphene quantum dot nanocomposite hydrogels

Massoudi, Solmaz; Bagheri, Massoumeh; Khosrowshahi, Younes Beygi; Hosseini, Maryam

doi:10.1007/s00289-022-04371-3

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of PVI for biomedical applications alone [249] or in combination with other polymers such as poly(acrylamide) [250] or chitosan [248] has already been exploited. Particularly, due to the presence of the imidazole group, PVI has been reported to present significant antibacterial activity [251,252].…”

Section: Gene Therapymentioning

confidence: 99%

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Domingues,

Jarak,

Veiga

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The paradigm of pediatric drug development has been evolving in a “carrot-and-stick”-based tactic to address population-specific issues. However, the off-label prescription of adult medicines to pediatric patients remains a feature of clinical practice, which may compromise the age-appropriate evaluation of treatments. Therefore, the United States and the European Pediatric Formulation Initiative have recommended applying nanotechnology-based delivery systems to tackle some of these challenges, particularly applying inorganic, polymeric, and lipid-based nanoparticles. Connected with these, advanced therapy medicinal products (ATMPs) have also been highlighted, with optimistic perspectives for the pediatric population. Despite the results achieved using these innovative therapies, a workforce that congregates pediatric patients and/or caregivers, healthcare stakeholders, drug developers, and physicians continues to be of utmost relevance to promote standardized guidelines for pediatric drug development, enabling a fast lab-to-clinical translation. Therefore, taking into consideration the significance of this topic, this work aims to compile the current landscape of pediatric drug development by (1) outlining the historic regulatory panorama, (2) summarizing the challenges in the development of pediatric drug formulation, and (3) delineating the advantages/disadvantages of using innovative approaches, such as nanomedicines and ATMPs in pediatrics. Moreover, some attention will be given to the role of pharmaceutical technologists and developers in conceiving pediatric medicines.

show abstract